Predictors of survival in patients with non-curative stage IV cancer and malignant bowel obstruction

Journal of Surgical Oncology

Volumn 101, Issue 5, 2010, Pages 425-429

  Wright, F C ^a   Chakraborty, A ^a   Helyer, L ^b   Moravan, V ^c   Selby, D ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c Applied Statistician   (Canada)

Author keywords

ECOG; Malignant bowel obstruction; Palliative; Predictors; Survival

Indexed keywords

ALBUMIN; NITROGEN; UREA;

ALBUMIN BLOOD LEVEL; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; EASTERN COOPERATIVE ONCOLOGY GROUP SCORE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INTESTINE CANCER; INTESTINE OBSTRUCTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 77950529139     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21492     Document Type: Article

References (25)

1. Anthony T, Baron T, Mercadante S, et al.: Report of the clinical protocol committee: Development of randomized trails for malignant bowel obstruction. J Pain Symptom Manage 2007; 34:S49-S59.
2. Krouse RS, McCahill LE, Easson A, et al.: When the sun can set on an unoperated bowel obstruction: Management of malignant bowel obstruction. J Am Chem Soc 2002;195:117-128.
3. Ripamonti C, DeConno F, Ventafrridda V, et al.: Management of bowel obstruction in advanced and terminal patients. Ann Oncol 1993;4:15-21.
4. Laval G, Girardier J, Lassauniere JM, et al.: The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: Do they remove the obstruction? Palliat Med 2000;14:3-10.
5. Mystakidou K, Tsilika E, Kalaidopoulou O, et al.: Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: A randomized, double- blind, controlled clinical trial. Anticancer Res 2002;22:1187-1192.
6. Mercadante S, Ripamonti C, Casuccio A, et al.: Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000;8:188-191.
7. Ripamonti C, Mercadante S, Groff L, et al.: Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 2000;19:23-34.
8. Shima Y, Ohtsu A, Shirao K, et al.: Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanses cancer patients with malignant bowel obstruction. Jpn J Clin Oncol 2008;38:354-359.
9. Laval G, Arvieux C, Stefani L, et al.: Protocol for the treatment of malignant inoperable bowel obstruction: A prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manage 2006;31:502-512.
10. Helyer LK, Law CHL, Butler M, et al.: Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol 2007;14:1264-1271.
11. Higashi H, Shida H, Ban K, et al.: Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer. Jpn J Clin Oncol 2003;33:357-359.
12. Glare P: Clinical predictors of survival in advanced cancer. J Support Oncol 2005;3:331-339.
13. Ripamonti C, Twycross R, Baines M, et al.: Clinical practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001;9:223-233.
14. Weiss SM, Skibber JM, Rosata FE: Bowel obstruction in cancer patients: Performance status as a predictor of survival. J Surg Oncol 1984;25:15-17.
15. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet 1985;2:990-993.
16. Vigano A, Bruera E, Jhangri GS, et al.: Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-868.
17. Barbot AC, Mussault P, Ingrand P, et al.: Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol 2008;26:2538-2543.
18. Stone P, Kelly L, Head R, et al.: Development and validation of a prognostic scale for use in patients with advanced cancer. Palliat Med 2008;22:711-717.
19. Kelly L, White S, Stone PC, et al.: the B12/CRP index as a simple prognostic indicator in patients with advanced cancer: A confirmatory study. Ann Oncol 2007;18:1395-1399.
20. Glare P, Sinclair C, Downing M, et al.: Predicting survival in patients with advanced cancer. Eur J Cancer 2008;44:1146-1156.
21. Yazdi GP, Miedema BW, Humphrey LJ: High mortality after abdominal operation in patients with large-volume malignant ascites. J Surg Oncol 1996;63:93-96.
22. Glockzin G, Schlitt HJ, Piso P: Peritoneal carcinomatosis: Patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009;7:5.
23. Verwaal V, Ruth S, Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intra-peritoneal chemotherapy versus systemic therapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737-3743.
24. Verwaal V, Bruin S, Boot H, et al.: 8-year follow up of a randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-2432.
25. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22:3284-3292.